Observing the effects of rimegepant on migraine treatment in the Greater Bay Area
A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area
This study is trying to see how well rimegepant works for treating migraines and improving the daily lives of people in the Greater Bay Area.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06221267 on ClinicalTrials.gov |
What this trial studies
This observational registry study aims to enroll 120 migraine patients treated with rimegepant at outpatient clinics in the Greater Bay Area. It will assess the effectiveness of rimegepant in a real-world clinical setting, focusing on its impact on patients' quality of life, functioning, productivity, and overall satisfaction. The study will follow participants for four weeks to gather comprehensive data on their experiences and outcomes while using rimegepant.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old with migraines as defined by the International Classification of Headache Disorders, who are prescribed rimegepant.
Not a fit: Patients with secondary headaches or those with severe impairments that prevent them from participating in the study may not benefit.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the real-world effectiveness of rimegepant for migraine treatment, potentially improving patient management strategies.
How similar studies have performed: While this study is observational, similar approaches have shown promise in evaluating real-world treatment effectiveness for migraines.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants with headaches that meet the diagnostic criteria for migraines according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), with or without aura. * Patients prescribed rimegepant by the attending physician for the treatment of migraines. * Signed informed consent form. * Age greater than 18 years. * Not concurrently participating in other interventional clinical studies. Exclusion Criteria: * Patients diagnosed with secondary headaches. * Patients with severe visual, auditory, language, intellectual, memory, consciousness impairments or other conditions that prevent them from completing the questionnaire and follow-up. * Pregnant or lactating female patients. * Patients deemed by the investigator as unsuitable for participation in the study or unable to complete the 4-week follow-up. * Patients with a known history of hypersensitivity reactions to rimegepant or its components. * Evidence in the medical history suggesting the presence of uncontrolled or unstable cardiovascular diseases (such as ischemic heart disease, coronary artery vasospasm, or cerebrovascular ischemia), or a history of myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke, or transient ischemic attack within the past 6 months before the screening visit.
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University — Guangzhou, Guangdong, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.